Envafolimab (Not yet branded)
Immunotherapy
Description
Envafolimab is a subcutaneous PD-L1 inhibitor monoclonal antibody designed for colorectal cancer treatment. Based on current clinical trials, it is being used in combination regimens for both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) colorectal cancers. The drug is administered with chemotherapy combinations like CAPEOX and mFOLFOXIRI, as well as with targeted agents such as cetuximab and bevacizumab for metastatic disease.
Mechanism of Action
Envafolimab binds to programmed death-ligand 1 (PD-L1) expressed on tumor cells and antigen-presenting cells, blocking the interaction between PD-L1 and PD-1 receptors. This blockade removes the inhibitory signal that suppresses T-cell activation, allowing the immune system to mount a more effective anti-tumor response against colorectal cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Immunotherapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Subcutaneous |
| Clinical Trials | 9 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.